SPOTLIGHT -
EP. 1: Understanding MDS Disease Characteristics and Progression
EP. 2: Classification and Prognosis in MDS
EP. 3: Factors to Consider in the Initial Treatment of MDS
EP. 4: Choosing Lenalidomide vs ESAs in Del 5q MDS
EP. 5: Transfusion Dependence in MDS: The Risk for Iron Overload
EP. 6: Monitoring Iron Levels in Transfusion-Dependent MDS
EP. 7: How Iron Accumulation Occurs in MDS
EP. 8: Negative Effects Associated with Iron Overload
EP. 9: Preventing and Diagnosing Iron Overload
EP. 10: The Impact of Excess Iron on Cardiac Function in MDS
EP. 11: The Role of Iron Chelation Therapy in Patients with MDS
EP. 12: Appropriate Use of Iron Chelators in MDS
EP. 13: MDS and Iron Overload: An Argument for Iron Chelation Therapy
EP. 14: Iron Chelation Therapy Efficacy and Safety in MDS
EP. 15: Iron Chelation Therapy in MDS: A Look at the Evidence
EP. 16: Factors to Consider in Iron Chelation Therapy
EP. 17: When a High-Risk Patient with MDS Might Be Low-Risk
EP. 18: The Future Role of Blood Transfusions in MDS
EP. 19: MDS: The Current Understanding in Molecular Testing and Biomarkers
EP. 20: Progress and Promise in the Treatment of MDS
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
